Recent advances in the search for D 3- and D 4- selective drugs: Probes, models and candidates

Trends in Pharmacological Sciences

Volumn 32, Issue 3, 2011, Pages 148-157

  Löber, Stefan ^a   Hübner, Harald ^a   Tschammer, Nuska ^a   Gmeiner, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 3 [[4 (4 IODOPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; ABT 614; ABT 670; ABT 724; ABT 925; ARIPIPRAZOLE; BP 897; CARIPRAZINE; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; FAUC 73; G PROTEIN COUPLED RECEPTOR; GSK 598809; GSK 618334; HALOPERIDOL; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; N [4 [2 (8 CYANO 1,3A,4,9B TETRAHYDRO 1 BENZOPYRANO[3,4 C]PYRROL 2(3H) YL)ETHYL]PHENYL]ACETAMIDE; OLANZAPINE; PD 128908; PERGOLIDE; PRAMIPEXOLE; RISPERIDONE; ROPINIROLE; ROTIGOTINE; UNCLASSIFIED DRUG;

ADDICTION; ALCOHOLISM; BINDING AFFINITY; BINDING SITE; CATALEPSY; COGNITIVE DEFECT; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SELECTIVITY; DRUG TARGETING; DYSKINESIA; ENZYME ACTIVATION; ERECTILE DYSFUNCTION; HUMAN; HYPERPROLACTINEMIA; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RADIOASSAY; RESTLESS LEGS SYNDROME; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; DOPAMINE AGONISTS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; LIGANDS; PIPERAZINES; PIPERIDINES; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952454207     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.12.003     Document Type: Review

References (97)

1. D.R. Sibley, and F.J. Monsma Jr. Molecular biology of dopamine receptors Trends Pharmacol. Sci. 13 1992 61 69
2. V. Cerezov High-resolution crystal structure of an engineered human beta 2-adrenergic G protein-coupled receptor Science 318 2007 1258 1265
3. A. Zhang Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders Chem. Rev. 107 2007 274 302 (Pubitemid 46237370)
4. 3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects Pharmacol. Ther. 112 2006 281 333 (Pubitemid 44301495)
5. F. Micheli, and C. Heidbreder Selective dopamine D3 receptor antagonists. a decade of progress: 1997-2007 Expert Opin. Ther. Pat. 18 2008 821 840
6. 4 receptor antagonists Curr. Pharm. Des. 3 1997 355 366
7. J.P. Overington How many drug targets are there? Nat. Rev. Drug. Discov. 5 2006 993 996 (Pubitemid 44835126)
8. J.-C. Schwartz The dopamine receptor family: molecular biology and pharmacology Semin. Neurosci. 4 1992 99 108
9. P. Seeman All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2 receptors CNS Neurosci. Ther. 2010 10.1111/j.1755-5949. 2010.00162.x
10. O. Prante Dopamine Receptor Subtype-Selective Drugs: D2-Like Receptors K.A. Neve, The Dopamine Receptors 2010 Humana Press 101 136
11. 3 dopamine receptor: neurobiology and potential clinical relevance Pharmacol. Rev. 49 1997 231 252 (Pubitemid 27414914)
12. 3 receptor agonists for protection and repair in Parkinsons disease Curr. Opin. Pharmacol. 7 2007 100 105 (Pubitemid 46238043)
13. 3) as a target for neuroleptics Nature 347 1990 146 151
14. 3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex Neuropsychopharmacol. 28 2003 839 849
15. 2 receptor antagonist and potential antipsychotic agent: iii. actions in models of therapeutic activity and induction of side effects J. Pharmacol. Exp. Ther. 324 2008 1212 1226 (Pubitemid 351397860)
16. M.J. Millan The dopamine D(3) receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures Int. J. Neuropsychopharmacol. 13 2010 1035 1051
17. 3 receptor as a useful polymorphism for investigating psychiatric disorders Psychiatr. Genet. 2 1992 249 256
18. 3 receptor is associated with risk and age-at-onset of essential tremor Proc. Natl. Acad. Sci. U.S.A. 103 2006 10753 10758 (Pubitemid 44078048)
19. M.J. Arranz, and J. de Leon Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research, pharmacogenetics and pharmacogenomics of schizophrenia Mol. Psychiatry 12 2007 707 747 (Pubitemid 47172693)
20. 3 receptor and risk for tardive dyskinesia in schizophrenic patients Int. J. Neuropsychopharmacol. 3 2000 61 65 (Pubitemid 30354454)
21. 3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49 2005 525 541 (Pubitemid 41169976)
22. 3 receptors J. Pharmacol. Exp. Ther. 326 2008 930 938
23. 3 receptor in the induction and expression of behavioural sensitization to ethanol in mice Psychopharmacol. 207 2009 47 56
24. 11C]-(+)-PHNO in drug-naïve Parkinsons disease Brain 132 2009 1366 1375
25. 4 receptor with high affinity for the antipsychotic clozapine Nature 350 1991 610 613
26. 4 signaling in prefrontal cortex J. Neurosci. 23 2003 9852 9861 (Pubitemid 37371599)
27. 4 receptor: biochemical and signalling properties Cell Mol. Life Sci. 67 2010 1971 1986
28. 4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial Biol. Psychiatry 55 2004 445 451 (Pubitemid 38338530)
29. 4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder Arch. Gen. Psychiatry 64 2007 921 931 (Pubitemid 47230616)
30. 4 receptor gene (DRD4) revisited in asians: haplotype characterization and relevance of the 2-repeat allele Am. J. Med. Genet. Part B 144B 2007 453 457 (Pubitemid 46983154)
31. D. Weintraub Impulse control disorders in parkinson disease. A cross-sectional study of 3090 patients Arch. Neurol. 67 2010 589 595
32. 4 polymorphism predicts the effect of L-DOPA on gambling behavior Biol. Psychiatry 67 2010 702 706
33. 4 receptors by ABT-724 induces penile erection in rats Proc. Natl. Acad. Sci. U.S.A. 101 2004 6758 6763 (Pubitemid 38586047)
34. M. Levite Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors Curr. Opin. Pharmacol. 8 2008 460 471
35. 4 receptors induce T cell quiescence by up-regulating Krüppel-like factor-2 expression through Inhibition of ERK1/ERK2 phosphorylation J. Immunol. 177 2006 7525 7529 (Pubitemid 44846267)
36. 3 receptor blockade on renal function and glomerular size in diabetic rats Naunyn-Schmiedebergs Arch. Pharmacol. 371 2005 420 427 (Pubitemid 41187514)
37. 4 dopamine receptor enhances angiotensin II- stimulated aldosterone secretion through PKC-ε and calcium signaling Am. J. Physiol. Endocrinol. Metab. 294 2008 E622 E629
38. C. Gebhard Amphetamines induce tissue factor and impair tissue factor pathway inhibitor: role of dopamine receptor type 4 Eur. Heart J. 31 2010 1780 1791
39. H.A. Nasrallah Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles Mol. Psychiatry 13 2008 27 35 (Pubitemid 350275185)
40. 2 receptor partial agonist Expert Opin. Investig. Drug 16 2007 771 775 (Pubitemid 46882352)
41. 3 receptor antagonists and partial agonists J. Med. Chem. 45 2002 4594 4597
42. 3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders Curr. Pharm. Des. 9 2003 643 671
43. 3 receptor ligands J. Med. Chem. 45 2002 5727 5735 (Pubitemid 35453765)
44. 3 receptor ligands J. Med. Chem. 46 2003 3883 3899 (Pubitemid 37034138)
45. 3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents J. Med. Chem. 48 2005 3663 3679 (Pubitemid 40776839)
46. 3 receptor antagonists J. Med. Chem. 52 2009 2559 2570
47. 3 receptor ligands: potential substance abuse therapeutic agents J. Med. Chem. 50 2007 4135 4146 (Pubitemid 47301745)
48. 3 receptor ligands Bioorg. Med. Chem. Lett. 19 2009 1773 1778
49. 4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding J. Med. Chem. 52 2009 4923 4935
50. 4 receptor J. Med. Chem. 39 1996 1941 1942 (Pubitemid 26163243)
51. M.A. Sanner Selective dopamine D4 receptor antagonists Exp Opin. Ther. Patents 8 1998 383 393 (Pubitemid 28160085)
52. 4 receptor: synthesis, ligand binding studies and comparison of molecular electrostatic potential maps Bioorg. Med. Chem. Lett. 9 1999 97 102
53. 4 receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments J. Med. Chem. 43 2000 4563 4569
54. 4 receptor subtype Bioorg. Med. Chem. Lett. 16 2006 2955 2959
55. 4 receptor ligands inducing penile erection ChemMedChem. 4 2009 325 328
56. 4 receptor ligands leading to the complete antagonist 2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213) J. Med. Chem. 44 2001 2691 2694
57. 4 ligands and models of receptor activation: 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning J. Med. Chem. 47 2004 2348 2355 (Pubitemid 38478858)
58. 35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors Br. J. Pharmacol. 161 2010 1238 1249
59. 3 receptor ligands leading to the prediction, synthesis and evaluation of rigidized FAUC 365 analogues Bioorg. Med. Chem. 14 2006 5898 5912 (Pubitemid 44080587)
60. 3 selective PET radioligands J. Med. Chem. 50 2007 489 500 (Pubitemid 46239783)
61. 3) receptor with a novel in vivo behavioral profile J. Med. Chem. 51 2008 5905 5908
62. Y. Zhao Computational modeling toward understanding agonist binding on dopamine 3 J. Chem. Inf. Model. 50 2010 1633 1643
63. 4 dopamine receptor uniquely influence the interactions of dopamine, norepinephrine, and Ro10-4548 J. Pharmacol. Exp. Ther. 333 2010 682 695
64. 3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system J. Recept. Signal Transduct. Res. 18 1998 133 150 (Pubitemid 28299116)
65. 2 receptor selectivity is determined by a divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments Mol. Pharmacol. 56 1999 1116 1126
66. 4 receptor interact with a common receptor microdomain Mol. Pharmacol. 66 2004 1491 1499 (Pubitemid 39564775)
67. 3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies J. Med. Chem. 51 2008 6829 6838
68. F. Micheli 1,2,4-Triazol-3-yl-thiopropyltetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists J. Med. Chem. 50 2007 5076 5089 (Pubitemid 47585705)
69. 3 receptor antagonists as pharmacotherapeutics for addictions and related disorders Ann. N. Y. Acad. Sci. 1187 2010 4 34
70. 3 receptor antagonists J. Med. Chem. 53 2010 374 391
71. 3 receptor with potent in vivo activity J. Med. Chem. 51 2008 3005 3019 (Pubitemid 351706028)
72. 2 receptors Mol. Pharmacol. 78 2010 925 934
73. T. Kenakin, and L.J. Miller Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 62 2010 265 304
74. 2L cell line: evidence for induction of ligand-specific receptor states Mol. Pharmacol. 66 2004 97 105 (Pubitemid 38822091)
75. i3 Mol. Pharmacol. 71 2007 1349 1359 (Pubitemid 46658688)
76. 2 receptor-mediated signaling pathways Neuropsychopharmacol. 32 2007 67 77 (Pubitemid 44967785)
77. + channel modulation in transfected cells Int. J. Neuropsychopharmacol. 11 2008 293 307 (Pubitemid 351482503)
78. Y. Han Allosteric communication between protomers of dopamine classA GPCR dimers modulates activation Nat. Chem. Biol. 5 2009 688 695
79. L. Albizu Time-resolved FRET between GPCR ligands reveals oligomers in native tissues Nat. Chem. Biol. 6 2010 587 594
80. 3 receptor function and trafficking by heterodimerization Mol. Pharmacol. 74 2008 59 69 (Pubitemid 351872159)
81. 1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia J. Neurosci. 29 2009 4829 4835
82. 3 receptor heteromers: pharmacological properties and therapeutic significance Curr. Opin. Pharmacol. 10 2010 100 107
83. 3 heteromeric complexes Mol. Pharmacol. 67 2005 400 407 (Pubitemid 40216732)
84. K. Fuxe Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders CNS Neurosci. Ther. 16 2010 e18 e42
85. P.S. Portoghese Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series Proc. Natl. Acad. Sci. U.S.A. 102 2005 19208 19213 (Pubitemid 43049591)
86. D. Huber 1,1′-Disubstituted ferrocenes as molecular hinges in mono- and bivalent dopamine receptor ligands J. Med. Chem. 52 2009 6860 6870
87. 3 selective antagonist Science 330 2010 1091 1095
88. 2-adrenergic receptor ligands Proc. Natl. Acad. Sci. U.S.A. 106 2009 6843 6848
89. A. Gautier Structure determination of the seven-helix transmembrane receptor sensory rhodopsin II by solution NMR spectroscopy Nat. Struct. Mol. Biol. 17 2010 768 775
90. S. Ferré Building a new conceptual framework for receptor heteromers Nat. Chem. Biol. 5 2009 131 134
91. 3 dopamine receptor-mediated inhibitory function Neuropsychopharmacol. 31 2006 2368 2375 (Pubitemid 44607053)
92. 3 dopamine receptor J. Recept. Signal Transduct. Res. 24 2004 117 130 (Pubitemid 39332213)
93. K.A. Neve Dopamine receptor signaling J. Recept. Signal Transduct. Res. 24 2004 165 205 (Pubitemid 39332216)
94. 2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile J. Pharmacol. Exp. Ther. 333 2010 328 340
95. 3 receptor ligands for the treatment of diseases of the central nervous system. PCT2001072306
96. 4 agonist for the treatment of erectile dysfunction J. Med. Chem. 49 2006 7450 7465 (Pubitemid 44913404)
97. M. Cowart Discovery of 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1H- benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction J. Med. Chem. 47 2004 3853 3864 (Pubitemid 38900350)